Blog
RSS FeedPosted by Michael Wonder on 25 Feb 2022
Noninvasix receives FDA breakthrough device designation for non-invasive monitoring technology for sepsis
23 February 2022 - LIVOx is first monitoring device to non-invasively monitor sepsis by detecting a key indicator of septic ...
Posted by Michael Wonder on 24 Feb 2022
FDA grants BI 1015550 breakthrough therapy designation for idiopathic pulmonary fibrosis
24 February 2022 - Designation is supported by Phase II efficacy and safety data that will be presented at ATS 2022. ...
Posted by Michael Wonder on 22 Feb 2022
NeuroSigma receives FDA breakthrough device designation for Monarch eTNS system
22 February 2022 - Monarch eTNS recognised as novel device for drug resistant epilepsy. ...
Posted by Michael Wonder on 16 Feb 2022
Bonalive Biomaterials granted FDA breakthrough device designation for a bone graft substitute that potentially protects against microbial colonisation
16 February 2022 - The Center for Devices and Radiological Health at the U.S. FDA has determined that Bonalive Orthopedics granules, ...
Posted by Michael Wonder on 16 Feb 2022
Foundation Medicine’s ctDNA monitoring assay, FoundationOne Tracker, granted breakthrough device designation by U.S. Food and Drug Administration
15 February 2022 - Foundation Medicine today announced that the U.S. FDA has granted a breakthrough device designation for its circulating ...
Posted by Michael Wonder on 16 Feb 2022
Cardiosense receives FDA breakthrough device designation for algorithm to identify patients at risk of decompensated heart failure
15 February 2022 - Cardiosense announced today that the U.S. FDA has granted the company breakthrough device status for its ...
Posted by Michael Wonder on 16 Feb 2022
Rapid Medical receives FDA breakthrough device designation for vasospasm treatment
15 February 2022 - Comaneci temporarily expands blood vessels, recognised as novel device for life-threatening disease. ...
Posted by Michael Wonder on 15 Feb 2022
Theradaptive wins additional FDA breakthrough designation for spinal fusion
15 February 2022 - Theradaptive announced that the U.S. FDA has granted breakthrough medical device designation for its OsteoAdapt SP Spinal ...
Posted by Michael Wonder on 14 Feb 2022
Bavarian Nordic announces breakthrough therapy designation for its RSV vaccine candidate for the prevention of respiratory syncytial virus in older adults
14 February 2022 - Bavarian Nordic announced today that the U.S. FDA has granted breakthrough therapy designation for the Company's vaccine ...
Posted by Michael Wonder on 14 Feb 2022
US FDA grants the coveted breakthrough designation for early stage prostate cancer detection blood test developed in India by Datar Cancer Genetics
14 February 2022 - It is the first blood test able to detect early stage prostate cancer with high accuracy ...
Posted by Michael Wonder on 04 Feb 2022
BioCardia receives FDA breakthrough device designation for CardiAMP cell therapy system for heart failure
3 February 2022 - BioCardia today announced that the U.S. FDA has granted breakthrough device designation for the CardiAMP Cell ...
Posted by Michael Wonder on 01 Feb 2022
Aussie device that gives eyes to the blind fast tracked in US
1 February 2022 - A world-first bionic eye that restores partial vision to the blind has been given “breakthrough” designation ...
Posted by Michael Wonder on 01 Feb 2022
Blue Note Therapeutics receives breakthrough device designation for prescription only digital therapeutic for acute myeloid leukaemia
31 January 2022 - Blue Note Therapeutics, a prescription digital therapeutics company dedicated to easing the burden of cancer and improving ...
Posted by Michael Wonder on 01 Feb 2022
Applaud Medical receives FDA breakthrough device designation for the company’s acoustic enhancer for use in conjunction with ureteroscopy with laser lithotripsy for the fragmentation of calcium based kidney stones
31 January 2022 - Applaud Medical today announced that its acoustic enhancer technology has received breakthrough device designation from the U.S. ...
Posted by Michael Wonder on 27 Jan 2022
FDA grants breakthrough therapy designation for Dizal Pharmaceutical's DZD9008 in patients with locally advanced or metastatic non-small cell lung cancer harbouring EGFR Exon 20 insertion
27 January 2022 - Breakthrough therapy designation further demonstrates excellent clinical profile of DZD9008 (sunvozertinib). ...